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Abstract
Background: Ingestion of groundwater with high concentrations of inorganic arsenic has been linked to adverse
health outcomes, including bladder cancer, however studies have not consistently observed any elevation in risk at
lower concentrations. Genetic variability in the metabolism and clearance of arsenic is an important consideration
in any investigation of its potential health risks. Therefore, we examined the association between genes thought to
play a role in the metabolism of arsenic and bladder cancer.
Methods: Single nucleotide polymorphisms (SNPs) in GSTO-1, As3MT and MTHFR were genotyped using DNA from
219 bladder cancer cases and 273 controls participating in a case–control study in Southeastern Michigan and
exposed to low to moderate (<50 μg/L) levels of arsenic in their drinking water. A time-weighted measure of
arsenic exposure was constructed using measures from household water samples combined with past residential
history, geocoded and merged with archived arsenic data predicted from multiple resources.
Results: While no single SNP in As3MT was significantly associated with bladder cancer overall, several SNPs were
associated with bladder cancer among those exposed to higher arsenic levels. Individuals with one or more copies
of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95%
CI = 1.04-1.32 per 1 μg/L increase in average exposure). However, no association was observed between average
arsenic exposure and bladder cancer among TT homozygotes in the same SNP. Bladder cancer cases were also 60%
less likely to be homozygotes for the A allele in rs1476413 in MTHFR compared to controls (OR = 0.40; 95%
CI = 0.18-0.88).
Conclusions: Variation in As3MT and MTHFR is associated with bladder cancer among those exposed to relatively
low concentrations of inorganic arsenic. Further investigation is warranted to confirm these findings.
Keywords: Genetic epidemiology, Single nucleotide polymorphisms, Urothelial cancer, Arsenic methylation
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Background
Cancer of the urinary bladder (or bladder) is the seventh
most common malignancy worldwide among men and
the 17th among women with approximately 386,000 new
cases diagnosed each year [1,2]. In the United States (U.
S.), bladder cancer is the fourth most common cancer
diagnosed among men and the eleventh among women
with a projected 73,510 new cases to be diagnosed in
2012 [3]. A vast majority of bladder tumors arise in the
urothelium and the most common histology is transi-
tional cell carcinoma (TCC).
Ingestion of inorganic arsenic primarily from ground-
water supplies has been linked to a number of adverse
health conditions including both benign and malignant
skin lesions, peripheral vascular disease and cancers of
the kidney, lung and bladder [4,5]. The data to support
these relationships were first gathered from investiga-
tions in areas of chronic and endemic arseniasis, how-
ever, in the past decade there has been an increasing
amount of attention devoted to study of the health con-
sequences of low to moderate concentrations of arsenic
consumed from contaminated household drinking water
(<100 μg/L). While studies in Argentina, Finland and
the U.S. indicate an increased risk of bladder cancer
among smokers exposed to higher levels of arsenic, they
do not report any increase in risk overall associated with
concentrations in this range [6-9]. In a recent report,
our findings from a population-based case–control study
conducted in Southeastern Michigan are in agreement
with other U.S. studies indicating no significant associ-
ation overall between arsenic exposure from drinking
water and bladder cancer risk [10]. However the limita-
tions inherent in the design of these studies, particularly
the difficulty in estimating arsenic exposure over an
extended period of time to account for the long-
induction latency period for cancer, introduces the possi-
bility of exposure misclassification which may explain
the null findings. Results have not been uniformly nega-
tive, as studies in Northeastern Taiwan, Chile and others
in Argentina have reported increases in bladder cancer
risk and mortality associated with arsenic concentrations
as low as 10-50 μg/L depending upon the length of ex-
posure [11-15].
Crucial to any investigation of an environmental expos-
ure such as arsenic and potential health risks is the consid-
eration of interindividual variability in its metabolism and
clearance. The primary pathway for the metabolism of in-
organic arsenic is methylation to monomethylated (mono-
methylarsonic acid [MMAV+], monomethylarsonous acid
[MMAIII+]) and eventually dimethylated (dimethylarsinic
acid [DMAV+], dimethylarsinous acid [DMAIII+]) forms
[16]. In humans, the process is incomplete and all forms
are excreted in urine in varying proportions, with arsenite
and monomethylated forms considered the most bioactive
and linked to enhanced risk of arsenic-induced health
hazards including bladder cancer [17-20]. The typical urine
profile in populations exposed to inorganic arsenic con-
tains 10-30% inorganic arsenic, 10-20% MMA and 60-80%
DMA [16]. The interindividual variation in the relative pro-
portion of inorganic arsenic and its methylated metabolites
excreted in urine has been attributed to differences in gen-
der, age, pregnancy, smoking behavior and diet [21]. More-
over, genetics have long been suspected to play an important
role in arsenic metabolism [21,22]. Polymorphisms in a
number of genes have been associated with variation in
methylation capacity with Glutathione S-Transferase
Omega-1 (GSTO-1), Methylene-tetrahydrofolate Reductase
(MTHFR) and Arsenic (+3) Methyltransferase (As3MT) as
three of the more widely investigated genes [23-33].
Therefore, we set out to examine the association be-
tween specific polymorphisms in each of these genes
with bladder cancer in a pilot case–control study. This
study is one of the first to investigate the interaction be-
tween genes involved in arsenic metabolism and lifetime
arsenic exposure on risk of bladder cancer conducted in
a residentially stable population in Southeast Michigan.
Methods
A population-based case–control study was conducted in
eleven counties in Southeastern Michigan based on evi-
dence of moderately elevated (<100 μg/L) arsenic concen-
trations in groundwater supplies. It has been estimated
that approximately 8% of the total population in the coun-
ties from which our participants were selected are exposed
to arsenic concentrations which exceed the Maximum
Contaminant Level (MCL) of 10 μg/L set by the U.S. En-
vironmental Protection Agency [34]. A detailed summary
of study methods has been previously reported [10]. Eli-
gible participants were residents of Genesee, Huron, Ing-
ham, Jackson, Lapeer, Livingston, Oakland, Sanilac,
Shiawasee, Tuscola and Washtenaw counties for at least
5 years prior to diagnosis (bladder cancer cases) and inter-
view (controls). Bladder cancer cases diagnosed between
January 1st, 2000 and December 31st, 2004 were identified
from the Michigan Cancer Surveillance Program, the
state’s cancer registry, within the Division of Vital Records,
Michigan Department of Community Health. Cases were
aged 21 to 80 years at date of diagnosis, histopathologically
confirmed, with no history of invasive cancer prior to blad-
der cancer diagnosis. Of the 1,634 potentially eligible cases,
25% (n= 411) completed all phases of the initial study
protocol. The most common reasons for non-participation
were 1.) refusing permission to registry for initial release of
contact information (41%); and 2.) death prior to registry
contact (22%). Disease-free controls were identified
through random-digit dialing and frequency matched to
cases by age (± 5 years), gender and race. Among the 2,132
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eligible controls identified, 27% (n= 566) completed all
phases of the initial protocol.
All participants completed a computer-assisted tele-
phone interview conducted by trained interviewers from
the Michigan Public Health Institute (MPHI). The inter-
view collected information on demographics, water and
other fluid consumption both at home and away from
home, a dietary questionnaire, smoking, medical and oc-
cupational history. Patterns of fluid consumption over
the participant’s adult lifetime were reported, including a
detailed characterization of any major changes in fluid
consumption. After the initial interview, research team
members scheduled a visit to the home of each partici-
pant to collect complete residential and occupational
histories. Participants were asked to provide information
on duration of residence/employment, drinking water
source at each location, change in water source and a
street address (or nearest cross streets). Each residence
in the study area was geocoded and assigned a specific
coordinate in ArcGIS (v.9.0; ESRI, Redlands, CA) with
no geocoding of residences outside the study area. Dur-
ing the in-home interview, household water and biospe-
cimens were also collected.
A genetic component to the larger case–control study
was initiated in 2005, at the approximate midpoint in
subject recruitment. The protocol was amended to re-
quest that participants provide a saliva specimen during
their scheduled in-home visit. A total of 219 cases and
273 controls, representing ~98% of subjects recruited
during this time, submitted saliva samples for genetic
studies. Genomic DNA was isolated from these speci-
mens using the Puregene DNA Purification buccal cell
kit (Gentra Systems, Minneapolis, MN). All protocols
were reviewed and approved by the University of Mich-
igan Health Sciences Institutional Review Board and all
participants provided written informed consent.
Measure of lifetime arsenic exposure
Our approach for estimating average lifetime arsenic ex-
posure and analysis of household water samples has
been previously described [10,35]. Briefly, an estimation
of arsenic concentrations from past residences on public
well water supplies relied on data that were extracted
from the Michigan state arsenic database and via the
contact of specific municipality within the study area
where the participant reported a prior residency. Public
surface water supplies from past residences were
assigned the average measured level of surface water in
the study population (0.30 μg/L). For past private wells
inside the study area, a geostatistical model was devel-
oped for predicting arsenic concentrations [36]. For pub-
lic supplies or private wells outside of the study area,
arsenic concentrations were estimated using city
averages from the U.S. Geological Survey (USGS)
database [37]. Estimates of average lifetime residential
exposure to arsenic were constructed independent of
case–control status, combining the measured concentra-
tions from household water samples collected from the
subject’s current residence and data gathered from past
residences with the assumption that arsenic concentra-
tions were relatively stable within a particular well. This
assumption is supported by our own internal investiga-
tion [38] and in the literature [39]. The measure was
then weighted by duration of residence with an average
(in μg/L) calculated across the adult lifetime [10]. The
household water samples were analyzed for arsenic con-
centration using an inductively coupled plasma mass
spectrometry unit (ICP-MS, Model 7500c, Agilent Tech-
nologies, Santa Clara, CA) at the University of Michigan.
SNP selection and genotyping methods
A total of twelve single nucleotide polymorphisms (SNPs)
in GSTO-1 (rs4925, rs2282326), As3MT (rs1046778,
rs11191438, rs11191439, rs3740400, rs7085104) and
MTHFR (rs1801131, rs1801133, rs6541003, rs9651118,
rs4846048, rs1476413) were genotyped using Taqman SNP
genotyping assays (Applied Biosystems, Foster City, CA).
These SNPs were selected based upon previous citation/
functional relevance in the literature, or a minor allele fre-
quency of≥ 10% among CEPH (Centre d’Etude du Poly-
morphisme Humain) Utah European ancestry samples
(CEU) in HapMap and an ability to tag major haplotype
blocks within each gene in the same samples [40]. We used
the ABI PRISM 7900HT Sequence Detection System and
the SDS software (Applied Biosystems, version 2.1) to dis-
tinguish SNP alleles. PCR primers were purchased from
Invitrogen Life Technologies (Carlsbad, California) and are
available upon request. Each PCR reaction contained 25μL
total volume (2.5μL of 10X PCR Buffer (Invitrogen Life
Technologies, Inc.), 0.5 μL 50 mM MgCl2, 0.5μL 10 mM
dNTPs, 2.5 μL each of the two PCR primers at 5 μM con-
centration, 2 μL of template DNA at 20 ng/μL, 0.125 μL of
PlatinumTaq Polymerase (Invitrogen), and 14.375 μL of
H20. PCR products were cleaned using MinElute PCR
purification kit (Germantown, Massachusetts) and
sequenced using an ABI prism 3100 Genetic Analyzer
using Big Dye Terminator v1.1 chemistries (Applied Bio-
systems, Foster City, California). The average genotyping
call rate was 97.5%, with call rates≥ 94.6% for each SNP.
Undetermined samples from an assay were sequenced if
DNA was available, resulting in a final genotyping call rate
of 99.5%, with call rates≥ 98.8% for each SNP. A random
subset of samples (2%) were also duplicated and verified by
direct sequencing without discrepancy.
Statistical methods
Statistical analyses were performed using Statistical Ana-
lysis Software (SAS Institute Inc. v. 9.1, Cary, N.C.). All
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tests were evaluated using a two-sided hypothesis test
with statistical significance interpreted as having a p-
value less than or equal to 0.05. Differences in age, gen-
der, race, smoking history, average arsenic exposure and
the distribution of genotypes for each SNP between
bladder cancer cases and controls were tested using ei-
ther the Wilcoxon rank-sum test or a simple chi-square
test. For each SNP, we calculated the minor allele fre-
quency among controls (Table 1).
The observed genotype distribution for each SNP
among controls was tested for consistency with HWE
expectations using Pearson’s chi-square test. Linkage dis-
equilibrium (LD) between selected SNPs within each
gene was evaluated using the PLINK software package
(http://pngu.mgh.harvard.edu/purcell/plink) [41] Uncon-
ditional logistic regression was used to determine
whether genotypes within each SNP were associated
with bladder cancer under the log-additive, dominant
and recessive models. A post-hoc test comparing homo-
zygotes for the minor allele and heterozygotes each to
homozygotes for the major allele (the referent) was also
performed. Multivariable models simultaneously
adjusted for the effect of each SNP, age (continuous),
and smoking history (ever/never). Because adjustment
for race and gender did not alter the odds ratios, they
were not included in the final models. The joint effect of
each SNP and arsenic concentration was evaluated by
including an interaction term in the regression models
which combined genotype (dominant model) and aver-
age arsenic concentration measured continuously. Add-
itional analyses stratified by genotype were performed,
calculating odds ratios for bladder cancer associated
with arsenic measured both continuously and according
to quartiles in the distribution of exposure among con-
trols. The p-values presented in the tables correspond to
the β coefficient for the interaction term. Potential hap-
lotypes for As3MT were constructed from genotype data
and differences in haplotype frequency (excluding rare
haplotypes [<2%]) between cases and controls were
evaluated using the Haplo.stat software package http://
mayoresearch.mayo.edu/mayo/research/schaid_lab/soft-
ware.cfm. The same package was used to estimate the
association between haplotype (under a log-additive
model) and bladder cancer, adjusting for age and smok-
ing history [42].
Results
Relevant characteristics of the 219 bladder cancer cases
and 273 controls participating in the pilot investigation
are summarized in Table 2. By design, cases and controls
were similar with respect to age, race and gender. Ap-
proximately 75% of participants were men, 95% were
white and the mean age at diagnosis (among cases) and
at interview (among controls) was 66 years (standard
deviation ± 9.5 years). Bladder cancer cases were more
likely to report that they had either formerly smoked or
were current smokers at the time of diagnosis compared
to controls at time of interview (78% versus 53%; p
< 0.0001). Furthermore, the estimated mean number of
pack-years among smokers was higher among cases than
Table 1 Single nucleotide polymorphisms in Glutathione
S-Transferase Omega, Arsenic Methyltransferase and 5,10
Methylene-tetrahydrofolate Reductase
SNP{ Gene Major/Minor Allele† MAF (%)*
rs4925 GSTO-1 C/A (Ala140Asp) 32.5
rs2282326 GSTO-1 A/C 38.9
rs1046778 As3MT T/C 29.9
rs3740400 As3MT A/C 35.8
rs11191439 As3MT T/C (Met287Thr) 9.2
rs11191438 As3MT G/C 39.6
rs7085104 As3MT A/G 33.9
rs1801131 MTHFR A/C (Glu429Ala) 33.0
rs1801133 MTHFR C/T (Ala222Val) 33.5
rs6541003 MTHFR A/G 42.7
rs9651118 MTHFR T/C 19.1
rs4846048 MTHFR A/G 30.8
rs1476413 MTHFR G/A 29.4
* Minor Allele Frequency (%) among controls.
† Non-synonymous SNPs denoted with amino acid substitution.
{ SNP= single nucleotide polymorphism.
Table 2 Characteristics of Study Participants
Characteristic Bladder Cancer
Cases n = 219
Controls
n = 273
p-value*
Age (in years)† 66.5 (+/− 9.4) 66.7 (+/− 10.0) 0.85
Gender
Males 169 (77.2%) 195 (71.4%)
Females 50 (23.8%) 78 (28.6%) 0.15
Race
White 206 (94.1%) 260 (95.1%)
Black 5 (2.3%) 2 (0.8%)
Other 8 (3.7%) 11 (4.0%) 0.35
Smoking
Ever smoked 172 (78.5%) 146 (53.5%)
Never smoked 47 (21.5%) 127 (46.5%) <0.0001*
Pack years smoked †∞ 33.2 (+/− 22.7) 24.4 (+/− 19.8) 0.003*
Arsenic concentration in
water (TWA) in μg/L**
1.31 (3.37) 1.44 (3.27) 0.45
* Derived from either Chi-square or Wilcoxon-Rank Sum test.
TWA= Time-Weighted Average.
† Mean (± standard deviation).
∞ Among smokers.
** Median (interquartile range).
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controls. As has been reported in the larger case–control
study, there was no significant difference between geno-
typed cases and controls in lifetime average exposure to
arsenic (p = 0.45) with an estimated median concentra-
tion of 1.36 μg/L (interquartile range = 3.33 μg/L) in the
study population.
The genotype distribution observed for each of the
tested SNPs among controls was consistent with HWE.
Table 3 summarizes the findings of our post-hoc testing
of associations between genotype for each SNP and
bladder cancer risk adjusted for age and smoking his-
tory, however this adjustment produced little difference
from the crude estimates of risk. We did not observe
any significant associations between SNPs in GSTO-1,
As3MT and MTHFR and bladder cancer risk overall
with one exception. Bladder cancer cases were 60% less
likely to be homozygotes for the A allele in rs1476413 in
MTHFR compared to controls (OR= 0.40; 95% CI =
0.18-0.88).
We then stratified the study population according to
genotype, examining the differences in the distribution
between time-weighted average (TWA) of arsenic expos-
ure (divided into quartiles and measured continuously)
between cases and controls (Tables 4 and 5). There was
evidence for interaction between several of the SNPs in
As3MT and arsenic exposure. Among persons with one
or more copies of the C allele in rs11191439
(Met287Thr), higher average arsenic exposure was asso-
ciated with an increase in the odds of bladder cancer
(OR= 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase).
However, no association was observed between average
arsenic exposure and bladder cancer among individuals
who were TT homozygotes for the same SNP. This same
polymorphism was also associated with an increase in
the odds of bladder cancer among all study subjects,
however the estimate was not statistically significant
(OR= 2.75; 95%CI = 0.47-16.77 among CC homozy-
gotes). Interactions with SNPs rs3740400, rs11191438
and rs7085104 and arsenic exposure were also observed
(Table 4). These SNPs were in strong LD with one an-
other (r2 values ranging from 0.83-0.95) (Additional file
1: Table S1). And while there was nominal evidence for
interaction with the rs4925 SNP in GSTO-1 and arsenic
exposure, we not find evidence for interaction with
selected SNPs in MTHFR and arsenic (Table 5).
Haplotype-based association analyses for the As3MT
gene were consistent with the single SNP results
(Table 6). No evidence for an association between haplo-
types in the As3MT gene and bladder cancer was
detected when using the entire sample of participants.
There was, however, an association between the As3MT
haplotype which included the Met287Thr polymorphism
(compared to the most common or referent haplotype)
and bladder cancer for participants exposed to arsenic
concentrations higher than 3.72 μg/L (the uppermost
quartile) (OR= 3.90; 95% CI = 1.39-10.9), but not among
those exposed to lower concentrations.
Discussion
In 2006, the U.S. Environmental Protection Agency low-
ered the MCL for arsenic concentrations in drinking
water provided by public water supplies in the U.S. from
50 μg/L to 10 μg/L, in response to growing concern and
mounting evidence that inorganic arsenic was hazardous
to human health at relatively low levels [4,43]. Results
from studies conducted across several regions in the U.
S. generally do not indicate these levels elevate risk of
bladder cancer, however some studies report elevated
risks among certain subgroups in the population (i.e.
smokers) in conjunction with low-level arsenic exposure
[6,8-10]. Findings from the current investigation suggest
that possessing one or more copies of the Met287Thr
polymorphism in the As3MT gene (rs11191439),
coupled with higher average arsenic exposure is asso-
ciated with an increase in bladder cancer risk. Our study
population had levels of arsenic primarily below the
current MCL, therefore the findings pertain to potential
genetic susceptibility to effects of arsenic at relatively
low-levels.
While our study is the first to report an interaction be-
tween As3MT (10q24.32) and arsenic exposure on blad-
der cancer risk, these findings are consistent with
evidence gleaned from several other studies demonstrat-
ing that polymorphisms in As3MT are involved in the
methylation of inorganic arsenic [24-29,33,44]. A study
of urinary arsenic species in a Mexican population
exposed to arsenic at concentrations averaging 5 μg/L to
43 μg/L was the first to report that three polymorphic
sites in As3MT were associated with a higher ratio of
DMAV to MMAV, with a single polymorphism
(rs11191453) also associated with a higher ratio of
arsenite to MMAV in children, but not adults [33]. Sub-
sequent studies have pointed to the Met287Thr poly-
morphism as being associated with enhanced As3MT
enzymatic activity [45] and a higher percentage of MMA
to DMA in urine samples among individuals carrying at
least one copy of the variant (C) allele [24,29,44,46]. Fur-
thermore, the findings of Lindberg et al., suggest that
the influence of the Met387Thr polymorphism is greater
among men than women explaining approximately 20%
of the variation in methylation ability in men, but just
4% in women [47]. In a recent report, no association
was observed between any of eight tested SNPs in
As3MT and bladder cancer overall and no clear evidence
of effect modification by A3sMT genotype. However,
despite the study’s limited statistical power to address
interaction between arsenic exposure and genotype, a
number of the odds ratios reported among participants
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Table 3 Odds of bladder cancer by genotype in genes of interest (Adjusted Odds Ratios and 95% Confidence Intervals)
SNP Genotype Cases N (%) Controls N (%) Age and smoking-adjusted OR (95% CI)
GSTO-1
rs4925 C/C 97 (44.7) 123 (46.1) 1.00
C/A 98 (45.2) 113 (42.3) 1.14 (0.77 – 1.68)
A/A 17 (7.8) 30 (11.2) 0.82 (0.42 – 1.61)
C/C 1.00
C/A & A/A 1.07 (0.74 – 1.56)
rs2282326 A/A 84 (39.1) 104 (38.5) 1.00
A/C 97 (44.3) 122 (45.2) 1.03 (0.68 – 1.55)
C/C 34 (15.8) 44 (16.3) 1.07 (0.61 – 1.86)
A/A 1.00
A/C & C/C 1.04 (0.71 – 1.52)
As3MT
rs1046778 T/T 112 (52.1) 134 (49.3) 1.00
T/C 80 (37.2) 113 (41.5) 0.83 (0.56 – 1.24)
C/C 23 (11.4) 25 (9.2) 1.00 (0.53 – 1.91)
T/T 1.00
T/C & C/C 0.87 (0.60 – 1.26)
rs3740400 A/A 80 (37.0) 113 (41.7) 1.00
A/C 118 (54.6) 122 (45.0) 1.34 (0.90 – 2.00)
C/C 18 (8.3) 36 (13.3) 0.71 (0.37 – 1.36)
A/A 1.00
A/C & C/C 1.20 (0.82 – 1.75)
rs11191439 T/T 172 (80.0) 222 (82.2) 1.00
T/C 39 (18.1) 46 (17.0) 1.12 (0.69 – 1.82)
C/C 4 (1.9) 2 (0.7) 2.75 (0.47 – 16.77)
T/T
T/C & C/C 1.18 (0.74 – 1.90)
rs11191438 G/G 71 (32.7) 103 (37.9) 1.00
G/C 113 (52.1) 122 (44.9) 1.26 (0.84 – 1.90)
C/C 33 (15.2) 47 (17.3) 1.00 (0.57 – 1.74)
G/G 1.00
G/C & C/C 1.19 (0.81 – 1.76)
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Table 3 Odds of bladder cancer by genotype in genes of interest (Adjusted Odds Ratios and 95% Confidence Intervals) (Continued)
rs7085104 A/A 86 (39.5) 119 (43.9) 1.00
A/G 112 (51.4) 120 (44.3) 1.28 (0.87 – 1.90)
G/G 20 (9.2) 32 (11.8) 0.88 (0.46 – 1.68)
A/A
A/G & G/G 1.20 (0.82 – 1.74)
MTHFR
rs1801131 A/A 95 (43.6) 127 (46.7) 1.00
C/A 109 (50.0) 111 (40.8) 1.39 (0.94 – 2.05)
C/C 14 (6.4) 34 (12.5) 0.55 (0.28 – 1.11)
A/A 1.00
C/A & C/C 1.19 (0.82 – 1.72)
rs1801133 C/C 92 (42.0) 121 (44.3) 1.00
C/T 106 (48.4) 121 (44.3) 1.18 (0.80 – 1.75)
T/T 21 (9.6) 31 (11.4) 0.86 (0.45 – 1.62)
C/C 1.00
C/T & T/T 1.11 (0.77 – 1.62)
rs6541003 A/A 69 (31.7) 89 (32.8) 1.00
A/G 125 (57.3) 131 (48.3) 1.36 (0.91 – 2.10)
G/G 24 (11.0) 51 (18.8) 0.65 (0.36 – 1.18)
A/A 1.00
A/G & G/G 1.17 (0.79 – 1.75)
rs9651118 T/T 138 (63.0) 180 (65.9) 1.00
C/T 68 (31.1) 83 (30.4) 1.03 (0.69 – 1.54)
C/C 13 (5.9) 10 (3.7) 1.54 (0.63 – 3.71)
T/T 1.00
C/T & C/C
1.08 (0.74 – 1.59)
rs4846048
A/A 102 (47.0) 131 (49.2) 1.00
A/G 100 (46.1) 111 (40.8) 1.25 (0.85 – 1.85)
G/G 15 (6.9) 30 (11.0) 0.66 (0.33 – 1.32)
A/A
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Table 3 Odds of bladder cancer by genotype in genes of interest (Adjusted Odds Ratios and 95% Confidence Intervals) (Continued)
A/G & G/G 1.12 (0.78 – 1.63)
rs1476413 G/G 120 (55.1) 139 (51.3) 1.00
G/A 88 (40.4) 105 (38.8) 1.01 (0.69– 1.49)
A/A 10 (4.6) 27 (10.0) 0.40 (0.18 – 0.88)
G/G 1.00
G/A & A/A 0.88 (0.61 – 1.27)
{ Models simultaneously adjusted for SNP, age (continuous), smoking history (ever/never).
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exposed to higher arsenic concentrations were elevated,
but with wide confidence intervals [48].
Gomez-Rubio and colleagues caution against attribut-
ing enhanced arsenic methylation to any single SNP in
As3MT, or for that matter any one gene, as they identi-
fied a large (347 kb) region in strong LD including four
genes in addition to As3MT [49]. We observed strong
pairwise LD between three of four As3MT polymorph-
isms interacting with arsenic exposure (Additional file 1:
Table S1). However, the Met287Thr polymorphism did
not strongly co-segregate with the other tested SNPs.
Our results suggest that homozygotes for the more
Table 4 Odds of bladder cancer associated with As3MT SNPs and arsenic from drinking water (in quartiles†)
SNP Major allele homozygote Minor allele carrier
Cases n (%) Controls n (%) Age and smoking
adjusted OR (95% CI)
Cases n (%) Controls n (%) Age and smoking adjusted
OR (95% CI)
p-interaction
As3MT
rs1046778
Q1 30 (26.8) 33 (24.6) 1.00 30 (29.1) 35 (25.4) 1.00
Q2 29 (25.9) 30 (22.4) 0.93 (0.44 - 1.97) 23 (22.3) 39 (28.3) 0.71 (0.34 – 1.46)
Q3 25 (22.3) 34 (25.4) 0.81 (0.38 - 1.71) 23 (22.3) 34 (24.6) 0.77 (0.37 - 1.61)
Q4 28 (25.0) 37 (27.6) 0.74 (0.36 - 1.56) 27 (26.2) 30 (21.7) 1.14 (0.55 - 2.36)
Continuous{ 112 (45.5) 134 (54.5) 1.00 (0.95 – 1.05) 103 (42.7) 138 (57.3) 1.03 (0.99 – 1.08) 0.33
rs3740400
Q1 23 (28.8) 19 (16.8) 1.00 38 (27.9) 49 (31.0) 1.00
Q2 24 (30.0) 28 (24.8) 0.60 (0.25 - 1.43) 28 (20.6) 41 (25.9) 0.87 (0.45 - 1.69)
Q3 18 (22.5) 27 (23.9) 0.55 (0.22 - 1.36) 30 (22.1) 40 (25.3) 0.94 (0.49 - 1.82)
Q4 15 (18.8) 39 (34.5) 0.24 (0.10 - 0.60) 40 (29.4) 28 (17.7) 2.08 (1.06 – 4.07)
Continuous 80 (41.5) 113 (58.6) 0.96 (0.91 – 1.02) 136 (46.3) 158 (53.7) 1.08 (1.02 – 1.14) 0.006
rs11191439
Q1 48 (27.9) 46 (20.7) 1.00 13 (30.2) 21 (43.8) 1.00
Q2 44 (25.6) 57 (25.7) 0.71 (0.40 - 1.28) 7 (16.3) 11 (22.9) 0.96 (0.27 – 3.37)
Q3 39 (22.7) 58 (26.1) 0.62 (0.34 - 1.12) 9 (20.9) 10 (20.8) 1.68 (0.49 – 5.75)
Q4 41 (23.8) 61 (27.5) 0.61 (0.34 - 1.09) 14 (32.6) 6 (12.5) 6.88 (1.72 – 27.6)
Continuous 172 (43.7) 222 (56.4) 1.00 (0.97 - 1.04) 43 (47.3) 48 (52.8) 1.17 (1.04 – 1.32) 0.02
rs11191438
Q1 19 (26.8) 19 (18.4) 1.00 42 (28.8) 49 (29.0) 1.00
Q2 22 (31.0) 23 (22.3) 0.72 (0.28 - 1.84) 30 (20.5) 46 (27.2) 0.79 (0.42 - 1.49)
Q3 16 (22.5) 29 (28.2) 0.49 (0.19 - 1.26) 33 (22.6) 39 (23.1) 0.98 (0.52 - 1.86)
Q4 14 (19.7) 32 (31.1) 0.28 (0.10 - 0.74) 41 (28.1) 35 (20.7) 1.60 (0.85 – 3.03)
Continuous 71 (40.8) 103 (59.2) 0.96 (0.90 – 1.03) 146 (46.4) 169 (53.7) 1.04 (1.00 – 1.09) 0.04
rs7085104
Q1 25 (29.1) 20 (16.8) 1.00 35 (26.5) 48 (31.6) 1.00
Q2 26 (30.2) 30 (25.2) 0.59 (0.26 - 1.36) 28 (21.2) 39 (25.7) 0.99 (0.50 - 1.95)
Q3 20 (23.3) 28 (23.5) 0.57 (0.24 - 1.37) 29 (22.0) 39 (25.7) 0.99 (0.50 - 1.93)
Q4 15 (17.4) 41 (34.5) 0.23 (0.09 - 0.55) 40 (30.3) 26 (17.1) 2.46 (1.23 – 4.92)
Continuous 86 (42.0) 119 (58.1) 0.96 (0.91-1.01) 132 (46.5) 152 (53.5) 1.09 (1.03 – 1.16) 0.002
† Quartile distribution of average arsenic exposure for among all genotyped participants.
Q1 = 1st quartile (< 0.55 μg/L).
Q2 = 2nd quartile (0.55-1.45 μg/L).
Q3 = 3rd quartile (1.45-3.72 μg/L).
Q4 = 4th quartile (>3.72 μg/L).
{ Odds Ratio per one unit increase in the continuous measure of lifetime arsenic exposure by genotype adjusted for age and smoking history (ever/never).
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Table 5 Odds of bladder cancer associated with GSTO-1 and MTHFR SNPs and arsenic from drinking water†
SNP Major allele homozygote Minor allele carrier
Cases n (%) Controls n (%) Age and smoking adjusted OR (95% CI) Cases n (%) Controls n (%) Age and smoking adjusted OR (95% CI) p-interaction
GSTO-1
rs4925
Q1 29 (29.9) 31 (25.2) 1.00 29 (25.2) 37 (25.9) 1.00
Q2 22 (22.7) 34 (27.6) 0.71 (0.33 – 1.54) 28 (24.3) 34 (23.8) 1.00 (0.49 – 2.05)
Q3 23 (23.7) 34 (27.6) 0.71 (0.33 – 1.52) 26 (22.6) 30 (21.0) 1.12 (0.53 – 2.34)
Q4 23 (23.7) 24 (19.5) 1.23 (0.55 – 2.76) 32 (27.8) 42 (29.4) 0.90 (0.45 – 1.80)
Continuous 97 (44.1) 123 (55.9) 1.10 (1.02 – 1.18) 115 (44.6) 143 (55.4) 1.00 (0.96 – 1.03) 0.03
rs2282326
Q1 27 (32.1) 22 (21.2) 1.00 32 (24.4) 46 (27.7) 1.00
Q2 21 (25.0) 30 (28.8) 0.63 (0.28 – 1.44) 32 (24.4) 39 (23.5) 1.08 (0.55 – 2.11)
Q3 18 (21.4) 29 (27.9) 0.49 (0.21 – 1.13) 30 (22.9) 38 (22.9) 1.17 (0.59 – 2.32)
Q4 18 (21.4) 23 (22.1) 0.76 (0.32 – 1.84) 37 (28.2) 43 (25.9) 1.13 (0.59 – 2.17)
Continuous 84 (44.7) 104 (55.3) 1.06 (0.99 – 1.14) 131 (44.1) 166 (55.9) 1.01 (0.97 – 1.04) 0.21
MTHFR
rs1801131
Q1 27 (28.4) 34 (26.8) 1.00 34 (27.6) 34 (23.4) 1.00
Q2 23 (24.2) 42 (33.1) 0.68 (0.32 – 1.42) 30 (24.4) 27 (18.6) 1.07 (0.51 – 2.24)
Q3 23 (24.2) 25 (19.7) 1.04 (0.48 – 2.27) 26 (21.1) 43 (29.7) 0.64 (0.32 – 1.30)
Q4 22 (23.2) 26 (20.5) 1.00 (0.46 – 2.20) 33 (26.8) 41 (28.3) 0.86 (0.43 – 1.72)
Continuous 95 (42.8) 127 (57.2) 1.01 (0.96 – 1.05) 123 (45.9) 145 (54.1) 1.03 (0.99-1.08) 0.43
rs1801133
Q1 26 (28.3) 29 (24.0) 1.00 35 (27.6) 39 (25.7) 1.00
Q2 25 (27.2) 28 (23.1) 1.03 (0.47 – 2.22) 29 (22.8) 41 (27.0) 0.70 (0.35 – 1.41)
Q3 19 (20.7) 36 (29.8) 0.65 (0.30 – 1.42) 30 (23.6) 32 (21.1) 0.89 (0.44 – 1.81)
Q4 22 (23.9) 28 (23.1) 0.92 (0.42 – 2.02) 33 (26.0) 40 (26.3) 0.85 (0.43 – 1.69)
Continuous 92 (43.2) 121 (56.8) 1.07 (1.00 – 1.14) 127 (45.5) 152 (54.5) 0.99 (0.96 – 1.03) 0.05
rs6541003
Q1 17 (24.6) 22 (24.7) 1.00 44 (29.5) 45 (24.7) 1.00
Q2 16 (23.2) 29 (32.6) 0.72 (0.29 – 1.79) 37 (24.8) 40 (22.0) 0.89 (0.47 – 1.67)
Q3 18 (26.1) 19 (21.3) 1.06 (0.42 – 2.69) 31 (20.8) 49 (26.9) 0.68 (0.36 – 1.28)
Q4 18 (26.1) 19 (21.3) 1.20 (0.47 – 3.04) 37 (24.8) 48 (26.4) 0.80 (0.43 – 1.49)
Continuous 69 (43.7) 89 (56.3) 1.01 (0.96 – 1.05) 149 (45.0) 182 (55.0) 1.03 (0.98 – 1.08) 0.52
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Table 5 Odds of bladder cancer associated with GSTO-1 and MTHFR SNPs and arsenic from drinking water† (Continued)
rs9651118
Q1 37 (26.8) 45 (25.0) 1.00 24 (29.6) 23 (24.7) 1.00
Q2 37 (26.8) 46 (25.6) 0.90 (0.48 – 1.70) 17 (21.0) 23 (24.7) 0.73 (0.30 – 1.77)
Q3 32 (23.2) 42 (23.3) 0.88 (0.46 – 1.69) 17 (21.0) 26 (28.0) 0.66 (0.28 – 1.57)
Q4 32 (23.2) 47 (26.1) 0.84 (0.44 – 1.60) 23 (28.4) 21 (22.6) 1.01 (0.43 – 2.38)
Continuous 138 (43.4) 180 (56.6) 1.01 (0.97 – 1.06) 81 (46.6) 93 (53.5) 1.02 (0.97 – 1.08) 0.73
rs4846048
Q1 25 (24.5) 31 (23.7) 1.00 36 (31.3) 37 (26.2) 1.00
Q2 23 (22.5) 37 (28.2) 0.74 (0.34 – 1.59) 29 (25.2) 32 (22.7) 0.91 (0.45 – 1.84)
Q3 25 (24.5) 29 (22.1) 0.88 (0.41 – 1.93) 24 (20.9) 39 (27.7) 0.73 (0.36 – 1.49)
Q4 29 (28.4) 34 (26.0) 0.97 (0.46 – 2.05) 26 (22.6) 33 (23.4) 0.89 (0.44 – 1.83)
Continuous 102 (43.8) 131 (56.2) 1.01 (0.97 – 1.06) 115 (44.9) 141 (55.1) 1.03 (0.97 – 1.09) 0.65
rs1476413
Q1 30 (25.0) 32 (23.0) 1.00 31 (31.6) 35 (26.5) 1.00
Q2 29 (24.2) 46 (33.1) 0.66 (0.33 – 1.34) 24 (24.5) 23 (17.4) 1.14 (0.52 – 2.52)
Q3 32 (26.7) 27 (19.4) 1.20 (0.58 – 2.51) 17 (17.3) 41 (31.1) 0.48 (0.22 – 1.04)
Q4 29 (24.2) 34 (24.5) 0.87 (0.42 – 1.80) 26 (26.5) 33 (25.0) 0.96 (0.46 – 2.01)
Continuous 120 (46.3) 139 (53.7) 1.02 (0.98 – 1.06) 98 (42.6) 132 (57.4) 1.02 (0.96 – 1.09) 0.93
† Quartile distribution of average arsenic exposure for among all genotyped participants.
Q1 = 1st quartile (< 0.55 μg/L).
Q2 = 2nd quartile (0.55-1.45 μg/L).
Q3 = 3rd quartile (1.45-3.72 μg/L).
Q4 = 4th quartile (>3.72 μg/L).
{ Odds Ratio per one unit increase in the continuous measure of lifetime arsenic exposure by genotype adjusted for age and smoking history (ever/never).
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common allele in each of these SNPs (rs3740400,
rs11191438 and rs7085104) had a lower risk of bladder
cancer in conjunction with arsenic exposure, however
minor allele carriers were at an increased risk. Prior
investigations of rs3740400, or those observed in LD
with this particular SNP, suggest an altered DMA to
MMA ratio associated with the minor allele [28,29,50].
However, the observed racial and ethnic variation in al-
lele frequency and patterns of LD, coupled with the
worldwide geographic variability in not only exposure to
arsenic but other risk factors, make the comparison be-
tween previous findings and our own difficult and an
area deserving further investigation.
There was some evidence, albeit weak, to support an
interaction between the rs4925 SNP in GSTO-1 and ar-
senic exposure in this investigation. Specifically, there
was evidence of a positive association between arsenic
exposure and bladder cancer among those homozygous
wildtype for the GSTO-1 polymorphism that was not
present for those with at least one variant allele. GSTO-
1, also on chromosome 10 (10q25.1), has demonstrated
the ability to catalyze the reduction of MMAV to
MMAIII, considered the rate-limiting step in arsenic bio-
transformation [51]. A strong pattern of LD has been
demonstrated in European Americans among the more
common (MAF> 10%) polymorphisms identified [32].
The Ala140Asp (rs4925) polymorphism in GSTO-1 has
been the most widely-studied, linked to risk of pre-
cancerous skin lesions and cancer in arsenic-exposed
populations [26,52,53], however studies have not con-
firmed any association between specific variants in
GSTO-1 with the relative proportion of arsenic and its
metabolites [47,52,54].
A greater proportion of controls compared to cases
were homozygotes for a single polymorphism in MTHFR
(rs1476413). The function, if any, of this particular SNP is
unknown, however other polymorphisms in the MTHFR
gene have been linked to a number of cancers [55]. Find-
ings with respect to bladder cancer have been mixed
[23,31,56-59]. Methylene-tetrahydrofolate reductase is an
enzyme which plays a notable role in the metabolism of
folate, and also considered important in arsenic methyla-
tion [60]. The 677 C!T (Ala222Val) and 1298 A!C
(Glu429Ala) polymorphisms in MTHFR have been inves-
tigated relative to their influence on arsenic methylation
capacity suggesting that homozygotes for the variant T al-
lele in MTHFR 677 excrete a smaller proportion of DMA
to inorganic arsenic in their urine and the opposite effect
among homozygotes for the variant C allele in MTHFR
1298 compared to homozygotes for the wild-type for each
SNP [23,47]. We did not find an association with either of
these polymorphisms in our investigation.
Consideration of potential sources of bias is im-
portant in interpreting the findings from this investi-
gation and a description of potential bias in the
larger case–control study has been previously pub-
lished [10]. The participation rate was relatively low
(~25%) introducing the possibility of selection bias.
To address this, we compared known characteristics
of participating cases and potentially eligible, non-
participating cases and found no difference between
the two groups with respect to race, gender and
urban versus rural residency. However, because par-
ticipating cases were more likely to be diagnosed
with less invasive disease and at a younger age com-
pared to non-participating cases, our findings might
not be generalizable to older patients diagnosed with
advanced bladder cancer. As nearly one-quarter of
potentially eligible cases died prior to registry con-
tact, survival bias is a consideration. Deceased cases
were more likely than participating cases to reside in
rural areas versus urban areas at time of diagnosis
(10% versus 6%). As rural areas tend to have gener-
ally higher and more variable levels of arsenic expos-
ure, it is possible that arsenic exposure may be
associated with more aggressive disease and earlier
death producing a bias for the overall association be-
tween arsenic exposure and bladder cancer toward
the null. However, published findings to support this
notion are inconsistent [61-63]. The reasons for non-
Table 6 Common haplotypes in the As3MT gene and bladder cancer by average level of arsenic from drinking water
All Subjects *As ≤3.72 μg/L As >3.72 μg/L
Haplotype** Cases (%) Controls (%) OR{† (95% CI) Cases (%) Controls (%) OR (95% CI) Cases (%) Controls (%) OR (95% CI
T-T-G-T-A 57.5 58.3 1.00 58.1 55.2 1.00 55.4 67.5 1.00
C-G-C-T-G 22.0 22.7 0.97 (0.71 – 1.34) 20.8 24.3 0.78 (0.53 – 1.13) 25.4 17.9 1.92 (0.98 – 3.76)
T-G-C-C-G 11.1 9.3 1.20 (0.78 – 1.84) 9.9 11.0 0.86 (0.52 – 1.41) 14.5 4.4 3.90 (1.39 – 10.9)
C-T-C-T-A 6.0 5.5 1.14 (0.64 – 2.01) 7.1 5.3 1.42 (0.75 – 2.69) 2.8 6.4 0.54 (0.13 – 2.22)
* Time-weighted average arsenic (As) concentration across lifecourse; dichotomized at the approximate 75% percentile in.
distribution among controls.
† OR=odds ratio CI==confidence interval.
{ Adjusted for age and smoking history.
** Order of 5 As3MT SNPs in haplotype models (rs1046778, rs3740400, rs11191438, rs11191439, rs7085104).
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participation among eligible controls were unavailable;
however an evaluation of participating controls sug-
gested that they were geographically representative of
the general population of the study area and by de-
sign similar in distribution to the cases with respect
to age, gender and race. A more detailed description
of this evaluation and its findings has been previously
reported [10].
Lastly, because the genetic component did not
begin until the midpoint in recruitment, genetic ma-
terial was collected on just 492 (50.4%) of all study
participants. A comparison of characteristics between
participants with and without DNA found no differ-
ence between these groups by gender or smoking
history (data not shown). A higher proportion of par-
ticipants with DNA were white (95%) compared to
those without DNA (89%) and exposed to higher ar-
senic concentrations (median concentration among
those with DNA 1.39 μg/L compared to 1.00 μg/L
among those without). However, the differences were
similar between cases and controls and were a reflec-
tion of the overall composition of the study partici-
pants recruited in the latter half of the overall
investigation. Nearly all (~98%) subjects recruited
submitted a saliva specimen during their scheduled
in-home visit.
Misclassification of lifetime arsenic exposure is a poten-
tial source of bias and may have been introduced from ei-
ther inaccurate recall of residential history by participants
or lack of information on groundwater arsenic concentra-
tions for past residences on private wells. However, one of
the strengths of the study was the residential stability of
our population. On average, 80% of the person-years used
to construct the measure of average arsenic exposure were
spent in southeastern Michigan, with just 5% of reported
residential histories among subjects on private wells out-
side of the study area and inadequate for geocoding. We
do not anticipate that these sources of misclassification
would differ systematically by genotype or disease status
and would therefore tend to bias our results toward the
null. Lastly, the study was of limited power to detect mod-
est differences between genotype and bladder cancer risk
particularly when the “at-risk” allele frequency was less
common. And in the case of Met287Thr, imprecision in
the estimate of risk associated with higher arsenic exposure
due to the small number of exposed cases and controls.
The number of participants with arsenic levels greater than
the current MCL was prohibitively small to examine gene-
environment interaction at arsenic concentrations greater
than 10 μg/L.
Conclusions
Results from this pilot investigation suggest that vari-
ation in As3MT and MTHFR is associated with bladder
cancer among those exposed to relatively low arsenic
concentrations. The Met287Thr polymorphism in
As3MT, in particular, was associated with an increased
risk of bladder cancer among participants exposed to
higher levels of arsenic exposure. Interactions between
several other SNPs in As3MT and arsenic exposure were
also observed; however LD in the region makes it diffi-
cult to attribute findings to any single SNP. The under-
lying mechanism may also involve other genes in close
proximity to As3MT. Future studies in larger popula-
tions are clearly warranted to confirm these findings as
well as to broaden the exploration of genes to their po-
tential association with arsenic in bladder cancer. If vali-
dated, these findings highlight the importance of gene-
environment interaction in the evaluation of arsenic-
mediated health risks in populations exposed to even
low levels of arsenic.
Additional file
Additional file 1: Table S1. Pairwise linkage disequilibrium analysis of 5
selected single nucleotide polymorphisms in As3MT among participants
of University of Michigan Bladder Cancer Study.
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